Identification

Name
Fosinopril
Accession Number
DB00492  (APRD00526)
Type
Small Molecule
Groups
Approved
Description

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure
Thumb
Synonyms
  • (2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
  • (2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • (S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • Fosinopril
Product Ingredients
IngredientUNIICASInChI Key
Fosinopril SodiumNW2RTH6T2N88889-14-9TVTJZMHAIQQZTL-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FosinoprilTablet10 mgOralSanis Health Inc2017-04-11Not applicableCanada
FosinoprilTablet20 mgOralSanis Health Inc2017-04-11Not applicableCanada
Fosinopril TabletsTablet20 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Fosinopril TabletsTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Fosinopril-10Tablet10 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Fosinopril-20Tablet20 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Monopril Tab 10mgTablet10 mgOralBristol Myers Squibb1992-12-312013-06-17Canada
Monopril Tab 20mgTablet20 mgOralBristol Myers Squibb1992-12-312013-06-17Canada
Ratio FosinoprilTablet20 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada
Ratio FosinoprilTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fosinoprilTablet10 mgOralApotex Corporation2005-04-27Not applicableCanada
Apo-fosinoprilTablet20 mgOralApotex Corporation2005-04-27Not applicableCanada
Ava-fosinoprilTablet20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-fosinoprilTablet10 mgOralAvanstra Inc2011-11-282014-08-21Canada
FOSINOPRIL NaTablet10 mg/1OralApotex Corporation2005-05-182017-02-24Us
FOSINOPRIL NaTablet40 mg/1OralApotex Corporation2005-05-182017-02-24Us60505 2512 02 nlmimage10 ee3f775b
FOSINOPRIL NaTablet20 mg/1OralApotex Corporation2005-05-182017-02-24Us
Fosinopril SodiumTablet10 mg/1OralPhysicians Total Care, Inc.2004-05-18Not applicableUs
Fosinopril sodiumTablet10 mg/1OralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs
Fosinopril SodiumTablet40 mg/1OralAurobindo Pharma2011-03-30Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralEon Labs, Inc.2005-09-28Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAurobindo Pharma2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralHeritage2011-11-15Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralCitron Pharma LLC2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2005-07-06Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralGlenmark Pharmaceuticals Inc.,Usa2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralRanbaxy Inc.2004-12-20Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralCitron Pharma LLC2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralbryant ranch prepack2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralHeritage2011-11-15Not applicableUs
International/Other Brands
Acecor (SPA (Czech Republic)) / Monopril (Bristol-Myers Squibb) / Staril (BMS (United Kingdom))
Categories
UNII
R43D2573WO
CAS number
98048-97-6
Weight
Average: 563.6625
Monoisotopic: 563.301189343
Chemical Formula
C30H46NO7P
InChI Key
BIDNLKIUORFRQP-FKDWWROVSA-N
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
IUPAC Name
(2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid
SMILES
CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[[email protected]@H](C[[email protected]]1C(O)=O)C1CCCCC1)C(C)C

Pharmacology

Indication

For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications
Pharmacodynamics

Following oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.

Volume of distribution
Not Available
Protein binding

Fosinoprilat is ≥95% protein bound

Metabolism

Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.

Route of elimination

After oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.

Half life

12 hours

Clearance
  • 26 - 39 mL/min [healthy]
Toxicity

Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fosinopril Action PathwayDrug action
Fosinopril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fosinopril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Fosinopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Fosinopril.Approved, Investigational
AcebutololFosinopril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fosinopril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fosinopril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fosinopril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Fosinopril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Fosinopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril.Approved
AlmasilateAlmasilate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fosinopril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Fosinopril.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AloxiprinThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fosinopril.Approved, Illicit, Investigational
AlprenololFosinopril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanFosinopril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Fosinopril.Experimental, Investigational
AmifostineFosinopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Fosinopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Fosinopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Fosinopril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fosinopril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fosinopril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Fosinopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Fosinopril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Fosinopril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Fosinopril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fosinopril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fosinopril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fosinopril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fosinopril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fosinopril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Fosinopril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fosinopril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Fosinopril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Fosinopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fosinopril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fosinopril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Fosinopril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Fosinopril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Fosinopril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fosinopril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Fosinopril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fosinopril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fosinopril.Approved, Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fosinopril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Fosinopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Fosinopril.Illicit
BarnidipineFosinopril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilFosinopril may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fosinopril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Fosinopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Fosinopril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fosinopril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fosinopril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fosinopril.Approved
BepridilFosinopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Fosinopril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Fosinopril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fosinopril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Fosinopril.Experimental
BimatoprostFosinopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
BisoprololFosinopril may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Fosinopril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fosinopril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Fosinopril.Approved, Investigational
BQ-123Fosinopril may increase the hypotensive activities of BQ-123.Investigational
BretyliumFosinopril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Fosinopril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Fosinopril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fosinopril.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosinopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fosinopril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fosinopril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fosinopril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Fosinopril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosinopril.Approved, Investigational
BupranololFosinopril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Fosinopril.Approved
CadralazineCadralazine may increase the hypotensive activities of Fosinopril.Experimental
CafedrineFosinopril may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fosinopril.Approved
CandoxatrilFosinopril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilFosinopril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Fosinopril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fosinopril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Fosinopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fosinopril.Approved, Vet Approved, Withdrawn
CarteololFosinopril may increase the hypotensive activities of Carteolol.Approved
CarvedilolFosinopril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fosinopril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fosinopril.Approved, Investigational
CeliprololFosinopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fosinopril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Fosinopril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Fosinopril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosinopril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Fosinopril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fosinopril.Approved
CicletanineFosinopril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilFosinopril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fosinopril.Approved, Investigational
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Fosinopril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Fosinopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Fosinopril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Fosinopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fosinopril.Approved
CloranololFosinopril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fosinopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fosinopril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Fosinopril.Approved
CryptenamineFosinopril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fosinopril.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.Approved
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Fosinopril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.Approved, Investigational, Vet Approved
CyclothiazideFosinopril may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Fosinopril.Approved, Investigational
DelaprilFosinopril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Fosinopril.Approved
DersalazineThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineFosinopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fosinopril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Fosinopril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Fosinopril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Fosinopril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fosinopril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide.Approved, Investigational
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Fosinopril.Approved, Investigational
DiethylnorspermineFosinopril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Fosinopril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fosinopril.Experimental
DiflunisalThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fosinopril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Fosinopril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosinopril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fosinopril.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dipyridamole.Approved
DorzolamideFosinopril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fosinopril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Fosinopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Fosinopril.Approved, Investigational
DrospirenoneFosinopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fosinopril.Withdrawn
DuloxetineFosinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fosinopril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Fosinopril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fosinopril.Investigational
EfonidipineFosinopril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.Approved
EnalaprilFosinopril may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatFosinopril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Fosinopril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Fosinopril.Approved, Investigational
EpanololFosinopril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fosinopril.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Fosinopril.Approved
EpoprostenolFosinopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Fosinopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Fosinopril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Fosinopril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Fosinopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Fosinopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Fosinopril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Fosinopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Fosinopril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Fosinopril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fosinopril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fosinopril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosinopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fosinopril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fosinopril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fosinopril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Fosinopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fosinopril.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Fosinopril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fosinopril.Experimental
FelodipineFosinopril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fosinopril.Approved
FenoldopamFosinopril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fosinopril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fosinopril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fosinopril.Experimental
Ferulic acidFosinopril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fosinopril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fosinopril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fosinopril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fosinopril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fosinopril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.Experimental
FurazolidoneFurazolidone may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
GarlicThe serum concentration of Fosinopril can be decreased when it is combined with Garlic.Approved
GuacetisalThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzFosinopril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Fosinopril.Approved
GuanazodineFosinopril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineFosinopril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Fosinopril.Approved, Investigational
GuanoclorFosinopril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFosinopril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFosinopril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fosinopril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Fosinopril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Heparin.Approved, Investigational
HexamethoniumFosinopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Fosinopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Fosinopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fosinopril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Fosinopril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Fosinopril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Fosinopril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Fosinopril.Approved, Investigational
HydrotalciteHydrotalcite can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fosinopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fosinopril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Fosinopril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Fosinopril.Approved, Investigational
ImidaprilFosinopril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fosinopril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fosinopril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Fosinopril.Approved
IndenololFosinopril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fosinopril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fosinopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fosinopril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Fosinopril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Fosinopril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Fosinopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Fosinopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.Approved, Investigational
IronIron can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fosinopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fosinopril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fosinopril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Fosinopril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fosinopril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Fosinopril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fosinopril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fosinopril.Approved
LabetalolFosinopril may increase the hypotensive activities of Labetalol.Approved
LacidipineFosinopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostFosinopril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fosinopril.Approved, Investigational
LercanidipineFosinopril may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fosinopril.Approved, Investigational
LevodopaFosinopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Fosinopril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Fosinopril.Approved
LinsidomineFosinopril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilFosinopril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fosinopril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Fosinopril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Fosinopril.Experimental
LofexidineFosinopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fosinopril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fosinopril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Fosinopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fosinopril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fosinopril.Approved, Investigational
MacitentanFosinopril may increase the hypotensive activities of Macitentan.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fosinopril.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineFosinopril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fosinopril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Fosinopril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Fosinopril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fosinopril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fosinopril.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fosinopril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Fosinopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fosinopril.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Fosinopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Fosinopril.Approved
MethoserpidineFosinopril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Fosinopril.Approved
Methyl salicylateThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaFosinopril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Fosinopril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Fosinopril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fosinopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fosinopril.Approved
MetipranololFosinopril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Fosinopril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Fosinopril.Approved, Investigational
MetyrosineFosinopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilFosinopril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fosinopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Fosinopril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Fosinopril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Fosinopril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Fosinopril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fosinopril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Fosinopril.Approved, Investigational
MoexiprilFosinopril may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fosinopril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Fosinopril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Fosinopril.Approved, Investigational
MuzolimineFosinopril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fosinopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fosinopril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fosinopril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fosinopril.Approved
NadololFosinopril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fosinopril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fosinopril.Approved
NaftopidilFosinopril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fosinopril.Approved, Vet Approved
NebivololFosinopril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Fosinopril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fosinopril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Fosinopril.Withdrawn
NicardipineFosinopril may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Fosinopril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fosinopril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fosinopril.Approved
NiguldipineFosinopril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFosinopril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fosinopril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Fosinopril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Fosinopril.Approved
NitrendipineFosinopril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Fosinopril.Approved
NitroaspirinThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Fosinopril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Fosinopril.Approved
ObinutuzumabFosinopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Fosinopril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fosinopril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fosinopril.Approved
OmapatrilatFosinopril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Fosinopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fosinopril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fosinopril.Approved
OxprenololFosinopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fosinopril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosinopril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fosinopril.Approved
PargylinePargyline may increase the hypotensive activities of Fosinopril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fosinopril.Approved, Investigational
PenbutololFosinopril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
PentoliniumFosinopril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fosinopril.Approved, Investigational
PerindoprilFosinopril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Fosinopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Fosinopril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fosinopril.Approved, Investigational
PhenoxybenzamineFosinopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fosinopril.Withdrawn
PhentolamineFosinopril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fosinopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fosinopril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Fosinopril.Approved
PindololFosinopril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosinopril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Fosinopril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fosinopril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Fosinopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fosinopril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fosinopril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Fosinopril.Withdrawn
Platelet Activating FactorFosinopril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Fosinopril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Fosinopril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Fosinopril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Fosinopril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Fosinopril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Fosinopril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fosinopril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Fosinopril.Approved
PregabalinThe risk or severity of angioedema can be increased when Fosinopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Fosinopril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fosinopril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fosinopril.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fosinopril.Approved, Investigational, Vet Approved
PropranololFosinopril may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fosinopril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fosinopril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Fosinopril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fosinopril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.Approved
QuinaprilFosinopril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Fosinopril.Approved
QuinineQuinine may increase the hypotensive activities of Fosinopril.Approved
RamiprilRamipril may increase the hypotensive activities of Fosinopril.Approved
RasagilineRasagiline may increase the hypotensive activities of Fosinopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosinopril.Approved
RemikirenRemikiren may increase the hypotensive activities of Fosinopril.Approved
RescinnamineFosinopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Fosinopril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fosinopril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Fosinopril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Fosinopril.Approved
RisperidoneFosinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabFosinopril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fosinopril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fosinopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Fosinopril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Fosinopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Fosinopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fosinopril.Approved
Salicylic acidThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fosinopril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fosinopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Fosinopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
SelexipagFosinopril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fosinopril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fosinopril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fosinopril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fosinopril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Fosinopril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fosinopril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Fosinopril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Fosinopril.Approved, Investigational
SitaxentanFosinopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Fosinopril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Fosinopril.Approved, Investigational
Sodium phosphateFosinopril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.Approved
SpiraprilFosinopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Fosinopril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fosinopril.Investigational
St. John's WortThe metabolism of Fosinopril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Fosinopril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fosinopril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fosinopril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fosinopril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fosinopril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fosinopril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Fosinopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fosinopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
TalinololFosinopril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Fosinopril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fosinopril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril.Approved, Investigational
TemocaprilFosinopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Fosinopril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fosinopril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fosinopril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fosinopril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fosinopril.Approved
TerlipressinFosinopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineFosinopril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fosinopril.Approved, Investigational, Withdrawn
TheodrenalineFosinopril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Fosinopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fosinopril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Fosinopril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fosinopril.Approved
TiboloneFosinopril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenFosinopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Fosinopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fosinopril.Investigational
TipranavirThe serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Fosinopril.Approved, Investigational
TolazolineFosinopril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosinopril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fosinopril.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fosinopril.Approved
TolonidineFosinopril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Fosinopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Fosinopril.Approved
TorasemideTorasemide may increase the hypotensive activities of Fosinopril.Approved
TrandolaprilFosinopril may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fosinopril.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fosinopril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Fosinopril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Fosinopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Fosinopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Fosinopril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Fosinopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Fosinopril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fosinopril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Fosinopril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Fosinopril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Fosinopril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Fosinopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Fosinopril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fosinopril.Investigational
Trolamine salicylateThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Trolamine salicylate.Approved
TromethamineTromethamine can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UdenafilUdenafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
UnoprostoneFosinopril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Fosinopril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fosinopril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Fosinopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Fosinopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Fosinopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Fosinopril.Approved, Investigational
VincamineFosinopril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineFosinopril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideFosinopril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineFosinopril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Fosinopril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fosinopril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Fosinopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fosinopril.Approved, Investigational, Withdrawn
ZofenoprilFosinopril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fosinopril.Withdrawn
Food Interactions
  • Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
  • Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of fosinopril.
  • Take without regard to meals.

References

Synthesis Reference

Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, "Preparation of crystalline polymorphs of fosinopril sodium." U.S. Patent US20050010054, issued January 13, 2005.

US20050010054
General References
  1. David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791]
  2. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]
External Links
Human Metabolome Database
HMDB0014635
KEGG Drug
D00622
KEGG Compound
C07016
PubChem Compound
55891
PubChem Substance
46506495
ChemSpider
50469
ChEBI
5163
ChEMBL
CHEMBL3306578
Therapeutic Targets Database
DAP000582
PharmGKB
PA449710
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Fosinopril
ATC Codes
C09AA09 — FosinoprilC09BA09 — Fosinopril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (206 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionCardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension)1
2CompletedTreatmentDiabetic Nephropathies1
3CompletedPreventionCardiovascular Disease (CVD) / Microalbuminuria / Renal Diseases1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
4Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
Not AvailableUnknown StatusTreatmentAngiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Chronic Kidney Insufficiency / Proteinuria1

Pharmacoeconomics

Manufacturers
  • Apotex inc etobicoke site
  • Invagen pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Watson laboratories inc florida
  • Bristol myers squibb co pharmaceutical research institute
Packagers
Dosage forms
FormRouteStrength
TabletOral10 1/1
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral40 1/1
TabletOral
TabletOral10 mg
TabletOral20 mg
Prices
Unit descriptionCostUnit
Monopril HCT 10-12.5 mg tablet1.71USD tablet
Monopril 10 mg tablet1.68USD tablet
Monopril 40 mg tablet1.67USD tablet
Monopril 20 mg tablet1.62USD tablet
Fosinopril Sodium-HCTZ 10-12.5 mg tablet1.61USD tablet
Fosinopril Sodium-HCTZ 20-12.5 mg tablet1.61USD tablet
Fosinopril sodium 20 mg tablet1.25USD tablet
Fosinopril sodium 40 mg tablet1.25USD tablet
Fosinopril sodium 10 mg tablet1.21USD tablet
Monopril 20 mg Tablet1.1USD tablet
Monopril 10 mg Tablet0.91USD tablet
Apo-Fosinopril 20 mg Tablet0.61USD tablet
Fosinopril 20 mg Tablet0.61USD tablet
Jamp-Fosinopril 20 mg Tablet0.61USD tablet
Mylan-Fosinopril 20 mg Tablet0.61USD tablet
Novo-Fosinopril 20 mg Tablet0.61USD tablet
Ran-Fosinopril 20 mg Tablet0.61USD tablet
Apo-Fosinopril 10 mg Tablet0.51USD tablet
Fosinopril 10 mg Tablet0.51USD tablet
Jamp-Fosinopril 10 mg Tablet0.51USD tablet
Mylan-Fosinopril 10 mg Tablet0.51USD tablet
Novo-Fosinopril 10 mg Tablet0.51USD tablet
Ran-Fosinopril 10 mg Tablet0.51USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006344No1993-01-102010-01-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-153 °CNot Available
water solubilityInsolubleNot Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00101 mg/mLALOGPS
logP4.71ALOGPS
logP5.49ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.87ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.21 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity149.12 m3·mol-1ChemAxon
Polarizability61.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9532
Blood Brain Barrier-0.667
Caco-2 permeable-0.6561
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.6774
Renal organic cation transporterNon-inhibitor0.812
CYP450 2C9 substrateNon-substrate0.7028
CYP450 2D6 substrateNon-substrate0.8128
CYP450 3A4 substrateSubstrate0.6729
CYP450 1A2 substrateNon-inhibitor0.8913
CYP450 2C9 inhibitorNon-inhibitor0.7438
CYP450 2D6 inhibitorNon-inhibitor0.9004
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorNon-inhibitor0.7303
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6376
Ames testNon AMES toxic0.7141
CarcinogenicityNon-carcinogens0.8025
BiodegradationNot ready biodegradable0.8102
Rat acute toxicity2.8211 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9534
hERG inhibition (predictor II)Non-inhibitor0.5918
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0000900000-f61a6a8a62cc0c92102b
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0000900000-ed280398ec57e4a02dce
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0090300000-4e1c300644a39a64aefe
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0090000000-85f8c80f83290feea35c
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0090000000-e28a43e299ff58e3a6bc
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0010900000-a142ed389f6652d197f1
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-1090000000-833fa43a37b31e08737c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-1090000000-cda46913f10b57e39204
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-2290000000-8627963d14d5d091e338
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0229-7890000000-a5186e8ef5fa038d0a91
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03k9-9720000000-ff0242177e3d4ef6c38a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000f-0000900000-a2e65cd39ca7266f3a02
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0000900000-0eee13fe1a605e98c985
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00ku-0105900000-1253dd1cea86dcfde7f6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udl-0908200000-59ff4955c6e6b2d36435
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0901000000-e2b0d1bb8bfd4d6f7595
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0000900000-f625a00c8eb75cbf317d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6x-0409200000-5a18b8096c457898aa5f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-28e69824d7a0442561b6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-aa95f5f65aec2f92a48a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-2900000000-48b3327e8691a43ae029
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-6900000000-de8ad752f1c8f05aded2

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Phosphinic acid esters / Carboxylic acid esters / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Proline or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives / Dicarboxylic acid or derivatives / Monocyclic benzene moiety / Benzenoid
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
L-proline derivative, phosphinic ester (CHEBI:5163)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. [PubMed:2836111]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
  4. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on February 13, 2018 09:36